Moderator and Speaker Bios

Over 30 Years of Experience In Men’s Health
Past-President of the Canadian Urological Association
Incoming President of the International Society for Sexual Medicine
Professor Emeritus in the Department of Surgery, Division of Urology at St. Joseph’s Health Care in London, Ontario
More than 20 research awards from national and international research organizations
Author of over 250 publications

Specializing in men’s health, with expertise in erectile dysfunction management, Peyronie’s disease treatments, REZUM Prostatectomy, cosmetic circumcision, scrotoplasty and male factor infertility. Our London Ontario clinic offers state of the art investigation and treatment services.

The ability to perform high resolution imaging on-site and offering local, minimally invasive treatments for Erectile Dysfunction and Peyronie’s disease allows a rapid and comprehensive approach for men seeking a solution.

Dr. Brock specializes in microsurgical vasectomy reversals, scrotal and penile surgery performed at the Advanced Medical Group Surgical Center in London Ontario, a procedure which provides couples seeking restoration of fertility post-vasectomy a high likelihood of success.

Dr. Ben Chew is a scientist at the Stone Centre at Vancouver General Hospital and associate professor in the  Department of Urologic Sciences at the University of British Columbia (UBC). He has been on active staff at Vancouver General Hospital since July 2006. Originally from Duncan, BC, he graduated from UBC medicine in 1998 and completed his urology residency at the University of Toronto in 2003. His fellowship focused on kidney stones and minimally invasive surgery at the University of Western Ontario.

Dr. Chew’s research focuses on how kidney stones form and intestinal absorption of minerals that can form kidney stones (calcium and oxalate). He is also interested in biomaterials as they pertain to urinary devices. He is investigating new coatings and special drug-eluting materials for urinary catheters and stents in an attempt to make them more biocompatible and reduce device-related infection, encrustation, and patient discomfort.

Dr. Chew has published over 40 peer-reviewed articles and received several awards including the Best Endourology Paper Award at the World Congress of Endourology in 2009, the Best Scientific Paper at the World Congress of Endourology in 2005, the Best Abstract Prize for Stone Disease at the American Urological Association Annual Meeting in 2005 and 2008, and a Michael Smith Foundation for Health Research Scholarship and Vancouver Coastal Health Research Institute Surgeon Scientist scholarship. He has both peer-reviewed funding and funding from industry to continue his research in stone disease and biomaterials.

Dr. Dean S. Elterman completed his medical degree followed by residency in urologic surgery at the University of Toronto. He became a fellow of the Royal College of Physicians and Surgeons of Canada in 2011. Dr. Elterman completed a two-year fellowship in Voiding Dysfunction, Neuro-Urology, Female Urology and Pelvic Reconstruction at Memorial Sloan-Kettering Cancer Center and New York Presbyterian Hospital/Weill Cornell Medical College in New York City.

He is the Medical Director of the Prostate Cancer Rehabilitation Clinic at Princess Margaret Hospital Cancer Centre. He completed his Masters degree in Clinical Epidemiology and Health Services Research at Weill Cornell Graduate School of Medical Sciences.

Dr. Elterman’s clinical and research interests include male health, voiding dysfunction and reconstruction including novel technologies for BPH, incontinence (male sling/artificial urinary sphincter), sexual dysfunction (penile prosthetic surgery); female voiding dysfunction including overactive bladder (sacral neuromodulation). Dr. Elterman teaches BPH surgery and neuromodulation internationally including at the AUA and SIU meetings, and is a member of several professional societies.

Dr. Farcas is an Assistant Professor and Surgeon-Investigator in the Department of Surgery, Division of Urology, at the University of Toronto. She is a surgeon at St. Michael’s Hospital subspecializing in the areas of laparoscopic and robotic surgery, endourology, and renal transplantation. Dr. Farcas received her Master’s Degree in Engineering at McGill University and obtained her MD and residency training in Urology at the University of Toronto. She then completed a two year Endourological Society clinical fellowship at St. Michael’s Hospital. Her research interests are in surgical innovation and surgical device development as well as surgical simulation.

Areas of Specialty and Research Interests
Laparoscopic and robotic surgery, endourology, and renal transplantation.
Innovative engineering designs for surgical innovation and surgical simulation.

Affiliated Hospital(s)
St. Michael’s Hospital

Dr. Tony Finelli is a urologic oncologist and surgeon investigator at the University Health Network (UHN) in Toronto and a Full Professor at the University of Toronto. He is the Head of Urology at UHN, GU Site Lead at the Princess Margaret Cancer Center and was the inaugural GU Oncology Lead for the province of Ontario (Cancer Care Ontario).

Dr. Finelli’s research interests relate to the natural history of localized kidney and prostate cancers. He is also actively involved in clinical trials. He has published more than 120 peer-reviewed manuscripts and holds peer-reviewed funding for research in prostate and kidney cancer.

Dr. Finelli’s clinical practice focuses on the management of urologic malignancies with minimally invasive and robotic techniques. He has performed live surgery for instructional purposes in more than 10 countries. Dr Finelli is recognized nationally and internationally for his contributions to minimally invasive urologic oncology.

Dr. Ethan Grober is a native of Toronto, Canada. He is an Assistant Professor within the Division of Urology at the University of Toronto and site chief of Urology at Women’s College Hospital and full time faculty at the Sinai Health System.

Dr. Grober is a fellowship-trained specialist in Male Sexual & Reproductive Medicine and Surgery. He completed his medical school training at McMaster University in Ontario. Following medical school, Dr. Grober entered residency training in Urologic Surgery at the University of Toronto. During his residency, Dr. Grober participated in the Surgeon Scientist Program and obtained a Master’s Degree in Surgical Education. Dr. Grober completed his fellowship training in Male Reproductive Medicine and Surgery at the Baylor College of Medicine. Dr. Grober’s clinical activities focus on testosterone deficiency, male reproductive and sexual medicine, vasectomy reversal, and microsurgery. Dr. Grober’s research activities are directed towards the achievement of excellence in surgical education. Dr. Grober served as the chair of the 2021 CUA guidelines on Testosterone Deficiency.​

Dr. Hamilton completed his medical school and urology residency at the University of Toronto. During residency he completed a Masters of Public Health (MPH) from the University of North Carolina at Chapel Hill and a research fellowship at Duke University. Before joining the faculty, he completed a fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Centre in New York City.

His clinical practice focuses on management of genitourinary malignancies, with particular focus on prostate and testis cancers. This includes minimally invasive surgical techniques. His research interests focus on the epidemiology of urological malignancies and biomarkers in risk and progression of these diseases.

Dr. Sender Herschorn graduated from McGill University Medical School in 1972 and completed the University of Toronto Urology training program with in 1978. He completed clinical fellowships in urodynamics, incontinence, and reconstruction in 1979 at the Institute of Urology in London UK and Baylor College of Medicine in Houston Tx.

Dr. Sender Herschorn is Professor in the Division of Urology at the University of Toronto and attending Urologist at Sunnybrook Health Sciences Centre. He completed an 11-year term as University Chair and holder of the Martin Barkin Chair in Urological Research. He is past Chair of the University of Toronto Department of Surgery Academic Promotions Committee and is a Past-President of the Canadian Urological Association and past General Secretary of the International Continence Society.

Dr. Herschorn has been a senior investigator in clinical trials relating to functional urology. He has won undergraduate, postgraduate, and continuing education awards at the University of Toronto as well as the Zimskind Award of the Society for Urodynamics and Female Urology, the W.T. Aikins award from the University of Toronto Faculty of Medicine for excellence in undergraduate medical teaching, and a Lifetime Achievement Award from the Society for Urodynamics and Female Urology. He has been the Director of the University of Toronto Urology Update since its inception in 1992. In 2015, he received an American Urological Association Presidential Citation Award for contributions in research for the treatment of urinary incontinence and overactive bladder.

Dr. Herschorn has produced many scientific publications, among them the chapters on Vaginal Surgery for Prolapse and Incontinence for 2 editions of Campbell’s Urology and on Injectables for Urinary Incontinence for the recent and forthcoming editions. He is an Editorial Board Member of Canadian Urological Association Journal and Neurourology and Urodynamics. He was Chair of the Committee on Vesico-urethral Stenosis after Treatment for Prostate Cancer at the First International Consultation on Urethral Stricture Disease and Chair of the Committee on Surgery for Male Incontinence at the five International Consultations on Urinary Incontinence.

Dr. Herschorn has delivered presentations and lectures throughout Canada and in the United States, Europe, Asia, Australasia, Africa, and South America.

Dr. Anil Kapoor is currently Professor of Surgery (Urology & Oncology) at McMaster University/ St. Joseph’s Hospital in Hamilton, Ontario, Canada.  He obtained his MD from Dalhousie University. He is a Fellow of the Royal College of Physicians and Surgeons of Canada and a Diplomate of American Board of Urology. He is certified by the American Society of Transplant Surgeons, having obtained post-graduate training from the Cleveland Clinic Foundation in Renal Transplantation, Reno-Vascular surgery, and GU Oncology.

Dr. Kapoor is current Director of the Urologic Cancer Centre for Research & Innovation (UCCRI) at St. Joseph’s Hamilton, Head of the Genito-Urinary Oncology program at the Juravinski Cancer Centre, Co-Chair of the NCIC Kidney Cancer Disease Group, and Chair of the Kidney Cancer Research Network of Canada (KCRNC). He is a member of the Board of Directors of Kidney Cancer Canada (KCC). He has published over 300 peer-reviewed papers, 12 book chapters and over 200 abstracts in the fields of genito-urinary oncology (prostate cancer and kidney cancer), kidney transplantation, and urologic laparoscopy. He is current Head of the Clinical Trials Group at the McMaster Institute of Urology (MIU) and established the Kidney Cancer Centre at McMaster University in 2009.

Dr Wassim Kassouf completed a fellowship in urologic oncology at M. D. Anderson Cancer Center in Houston, Texas following medical school and urology residency at McGill University.  Dr. Kassouf’s clinical practice focuses on all aspects of urologic oncology (including bladder, prostate, renal, testes, and penile cancer) whereas his clinical and translational research program focuses on refining organ preservation approaches in bladder cancer. He is a tenured Professor in the Division of Urology and past Vice-Chair of academic affairs, for the Department of Surgery at McGill University.  He has also served as urology program director for 6 years and was a member of the Royal College Examination board committee.

He has led several national guidelines for optimizing quality of care in urologic cancer management and has published over 370 peer-review manuscripts and book chapters. His research supported by independent peer-reviewed grant funding from the US Dept of Defense, Canadian Institutes of Health Research, and Cancer Research Society. He is bladder cancer section editor for CUAJ and has served as associate editor for BMC Urology, and is/has been on the editorial board of Urology, Clinical Cancer Investigation Journal, and International Brazilian Journal of Urology. He is a cofounder of Bladder Cancer Canada, GU co-chair of the Canadian Clinical Trials Group, and an executive member of the NIH Genitourinary steering committee Bladder Cancer Task Force. Dr Kassouf is a graduate of the AUA Leadership Program and received several prestigious awards including the American Urological Association Young Urologist of the Year, AUA Research Scholar Award, Quebec FRQS Distinguished Research Scholar Award, Bladder Cancer Canada Medical Leadership Award, and the Everett C. Reid Teaching Excellence Award.

• B.A. Carleton University Psychology
• M.D. University of Toronto 1993
• FRCSC Urology University of Toronto 1998

• Staff Urologists Toronto East/Michael Garron Hospital 1998-present
• Division Head Urology, Toronto East/Michael Garron Hospital 2012-present
• President Medical Staff Association Toronto East General 2008-2009

• Chair Ontario Medical Association Section on Urology 2013-present
• Tariff Chair, Urology, Ontario Medical Association (2012-2013)

Dr. Rose Khavari earned her medical doctorate degree with highest honors from the University of Texas Medical Branch in Galveston, Texas, while serving as the president for Alpha Omega Alpha medical honor society. She completed her residency in Urology at Baylor College of Medicine, followed by a fellowship in male and female continence, pelvic floor reconstructive surgery, urogynecology and neurourology.

Dr. Khavari specializes in male and female incontinence, transitional urology, minimally invasive surgery, prolapse, neurogenic bladder, and urinary issues after prostate surgery.

Dr. Khavari is supported by NIH to investigate brain control over the bladder and has a multidisciplinary translational lab utilizing various fMRI platforms to accomplish this goal. She also serves as the program director for Urology Residency at Houston Methodist Hospital.

Twitter: @Rose Khavari

Yonah Krakowsky MD MEd FRCSC is a surgeon teacher and assistant professor in the Division of Urology, Department of Surgery at University of Toronto. He serves as the medical director of the Transition Related Surgery Program at Women’s College- Canada’s first publicly funded, academic gender surgery program. His clinical and academic interests are in gender surgery, peyronie’s disease and erectile dysfunction.

Dr. Girish Kulkarni is a urologic surgeon in the Department of Surgery at the Princess Margaret Cancer Centre, University Health Network where he serves as Head of the Division of Surgical Oncology. He is also a surgeon-scientist who is affiliated with the Department of Surgery, Faculty of Medicine at the University of Toronto. At the University of Toronto, he is an Associate Professor in the Department of Surgery, as well as in the Institute of Health Policy, Management and Education (IHPME) and is also a Senior Adjunct Scientist at the Institute for Clinical Evaluative Sciences. Dr. Kulkarni’s primary research interests revolve around the epidemiology of genitourinary malignancies, particularly prostate and bladder cancer. His investigations are dedicated towards the understanding of population-level quality of care from urologic malignancies, quality of life and the health economics associated with urologic malignancies, as well as determining the efficacy of clinical evaluation and treatment towards prostate and bladder cancer. He currently holds grant funding from the Canadian Institutes for Health Research, Bladder Cancer Canada and the Canadian Urologic Oncology Group.  He is Vice Chair of the Medical Research Board of Bladder Cancer Canada, serves as the Society of Urologic Oncology Fellowship Program Director for the University of Toronto and is the Genitourinary Cancers Lead at Cancer Care Ontario (Ontario Health).

Graduated from medical school and urology residency training at the Univ of Toronto. Completed fellowship training at UC Irvine in Endourology and MIS Surgery and now practicing at University Health Network (Toronto General Hospital) focusing on stone disease, robotic and laparoscopic surgery, renal transplantation. Associate Professor at University of Toronto. Clinical practice focuses on kidney stone disease and endourology, robotic surgery, renal transplantation. Program Director for Urology Residency Training Program

Dr. Lerner is an Associate Professor of Urology at Boston University School of Medicine, and serves as Chief of Urology and Deputy Chief of Surgery at VA Boston Healthcare System, and the New England Chief Surgical Consultant.  She is an international expert in laser surgery, Male Voiding Dysfunction, and benign prostate surgical therapies. She completed fellowship training in HoLEP and laser surgery in New Zealand. For the majority of her 20+ year career she has been within the Veterans Affairs medical system, but has also spent 9 years with time in the private sector in large private hospital systems.

An academic urologist her entire career, she has been involved in teaching HoLEP to residents and urologists at home, and abroad.  She is currently the Chair of the American Urological Association’s BPH Guidelines Committee and advocates conscientious approaches to benign prostate disease.  Dr. Lerner has also been involved in CAUTI initiatives, contributing to the American Urological Association’s White Paper on CAUTI.  She is a strong advocate of education about surgical energies, particularly lasers, and has been involved in numerous initiatives and courses promoting education and training.  She is also interested in, and has published about, issues of importance to women surgeons including pregnancy complications, fertility, and cancer.

Amy N. Luckenbaugh MD is a current Assistant Professor of Urology at Vanderbilt University Medical Center. She is a graduate of the University of Buffalo School of Medicine and Biomedical Sciences in Buffalo, New York. Dr. Luckenbaugh completed her 5-year residency in General Surgery and Urologic Surgery at the University of Michigan in Ann Arbor, Michigan. She then completed her 2-year Society of Urologic Oncology fellowship at Vanderbilt University Medical Center. Her clinical and research interests are focused on the care of patients with all urologic malignancies including cancers of the bladder, kidney, ureter, testis, prostate, adrenal gland and penis. She is the current secretary of the Society of Women in Urology Board.

Dr. Michael Ordon completed his medical school and urology residency at the University of Toronto. He became a fellow of the Royal College of Surgeons of Canada in 2010. Following his residency training he completed a two-year fellowship at St. Michael’s Hospital specializing in kidney stones, minimally invasive urologic surgery and renal transplantation. During his time he also completed a Master of Science in Clinical Epidemiology and Health Care Research through the Institute of Health Policy Management and Evaluation, at the University of Toronto. He also completed a second fellowship at the University of California Irvine focusing on image-guided ablation for small kidney tumours.

His primary research interest is in health services research with a particular focus on the epidemiology and treatment of kidney stone disease and outcomes research for renal transplantation.

Areas of Specialty and Research Interests
Surgical management of complex kidney stones, renal transplantation, laparoscopic urology, and robotic-assisted surgery, as well as image guided cryoablation of small renal tumours

Affiliated Hospital(s)
St. Michael’s Hospital

Dr. Pace graduated from the Faculty of Medicine at the University of Toronto in 1994. He completed his urology residency in Toronto in 1999, and then completed a Masters degree in Health Research Methodology at McMaster University and a 3-year fellowship in minimally-invasive surgery in 2002.
He joined St. Michael’s Hospital and the faculty of medicine at the University of Toronto in 2002. His practice focuses on laparoscopic and robotic-assisted surgery, the treatment of kidney stones, and kidney transplantation. He performed the first robotic-assisted prostatectomy in Toronto in March, 2007, and has an active practice in robotic-assisted surgery for both prostate and kidney cancer. He has been a leader in minimally-invasive (or laparoscopic) surgery since starting his practice, as well as a leader in the surgical treatment of kidney stones. He has been an invited lecturer across Canada, the United States, Europe, Australia, and Asia.
Dr. Pace is the head of the Division of Urology St. Michael’s Hospital in Toronto, and is the Chair of the St. Michael’s Hospital Medical Services Association, the alternative funding plan organization for all physicians at the hospital. He also serves as the Vice Chair of Urology, the co-director of the University of Toronto fellowship program in Urologic Laparoscopy and Endourology, and as the Division of Urology Clinical Fellowship Coordinator at the University of Toronto. Dr. Pace is the past-president of the Canadian Endourology Group, and the past-president of the Northeast Section of the American Urological Association.

Dr. Perlis completed his urological oncology SUO fellowship at the University of Toronto.  His clinical focus includes minimally invasive robotic surgery, image-guided therapeutics and diagnostics. Dr. Perlis is currently an investigator in several studies using novel technologies (HIFU, laser, PDT, porphysomes, IRE) in prostate cancer and has projects exploring the value of using patient-centred reports.

Dr. Aaron Pollett is the Provincial Head, Pathology and Laboratory Medicine Program at Ontario Health – Cancer Care Ontario. He is an Anatomic Pathologist and Co-Director of the Division of Diagnostic Medical Genetics at Mount Sinai Hospital and an associate professor in the department of Laboratory Medicine and Pathobiology at the University of Toronto.

Dr. Pollett has a speciality interest in gastrointestinal pathology and pathology informatics with a Master’s Degree from the Department of Health Policy, Management and Evaluation, University of Toronto. He is the review pathologist for tumour based registries constructed to analyze the genetic basis of gastrointestinal cancers.

In his various roles, Dr. Pollett oversees the molecular analysis of solid cancers as well as the development and implementation of molecular biomarkers.

Professor of Surgery (Urology), University of Toronto. Toronto Western Hospital (University Health Network). Graduated from the University of Toronto Medical School in 1984. Urology training at the University of Toronto. Fellowship training in voiding dysfunction, urodynamics and genitourinary prosthesis at both the University of Toronto and University of California (Davis). Clinical and research interests in the areas of erectile dysfunction, voiding dysfunction, incontinence, prostate diseases and urodynamics.  Director Urodynamics Laboratory Toronto Western Hospital.

Samir S. Taneja, MD is the James M. and Janet Riha Neissa Professor of Urologic Oncology; Professor of Urology, Radiology, and Biomedical Engineering; GU Program Leader in the Perlmutter Cancer Center; Director of the Division of Urologic Oncology, and Vice Chair in the Department of Urology at NYU Langone Health.

Dr. Taneja is nationally renowned as a leader in the treatment and research of prostate cancer.  Over the past decade, his clinical research interest has been in prostate cancer diagnostics, with particular focus on the application of imaging in the detection, risk stratification, and targeted therapy of prostate cancer.   He has pioneered the clinical application of pre-biopsy prostate MRI and techniques of MRI-targeted biopsy, and is widely recognized as an innovator in the emerging field of prostate cancer focal therapy. His previous laboratory research has focused in androgen receptor transcriptional activation and the relationship of AR to prostate cancer growth, for which he has received funding through the National Institutes of Health, Department of Defense, and the Prostate Cancer Foundation.

Dr. Taneja has previously served on the ABU Examination Committee, the SUO Oncology Knowledge Assessment Test Committee, the Society of Urologic Oncology Board of Directors, and he is previous Secretary General and past-President of the Urologic Research Society.  He is an oral examiner for the American Board of Urology and an elected member of the American Association of Genitourinary Surgeons. He has authored over 250 articles, 25 book chapters, and 5 textbooks.  He is the Urology Surveys prostate cancer contributor for the Journal of Urology, previous Consulting Editor of the Urologic Clinics of North America, and Editor of the 3rd, 4th, and 5th, and upcoming 6th editions of Taneja’s Complications of Urologic Surgery: Prevention and Diagnosis, one of the most widely read textbooks in American urology.

Emily is an American Board Certified Genetic Counselor with clinical roles in the Familial Cancer Clinic at the Princess Margaret Cancer Centre and the multidisciplinary Elisabeth Raab Neurofibromatosis clinic at Toronto General Hospital. She obtained her MSc Genetic Counselling degree from the University of Toronto. In addition to hereditary cancer, her interests include innovative models of genetics service delivery. She has led implementation of mainstreamed genetic testing with breast oncologists at Princess Margaret and has recently begun a similar initiative with GU oncologists. She is actively involved in teaching as a clinical supervisor and lecturer at the University of Toronto’s M.Sc. Genetic Counselling program.

Theo Van der Kwast is an active Staff Pathologist, University Health Network (since 2006), has been appointed as Full Professor, Dept. of Lab Medicine and Pathobiology at the Faculty of Medicine, University of Toronto since 2004. He was Professor of Pathology at the Erasmus Medical Center in Rotterdam, The Netherlands (appointed in 1995) prior to his move to the Department of Pathology, Mount Sinai Hospital in Toronto, Canada. His main research interests are the early detection of prostate cancer, biomarker development for bladder and prostate cancer and correlation of prostate pathology and imaging. Some of his earlier research accomplishments in the area of prostate cancer are the demonstration of persistent androgen receptor expression in endocrine therapy resistant prostate cancer, the stage and grade shift of prostate cancer as a consequence of population-based screening, the development of a more liberal definition of indolent prostate cancer and more recently his study of the prognostic role of intraductal carcinoma and invasive cribriform carcinoma. In bladder cancer he was involved in the identification of mutations in FGFR3 as a marker for low grade bladder cancer, the use of urine biomarkers in monitoring of non-muscle invasive bladder cancer and the improvement of pathological staging of bladder cancer. He served many years as Chair of the Pathology Committee of the European Randomized Screening Study of Prostate Cancer and he was Pathology Lead for the Canadian Prostate Cancer – Genome consortium. He is now Past-President of the International Society of Urological Pathology and member of the Guideline Committee on Prostate Cancer of the European Association of Urology. He has (co-authored) more than 500 peer-reviewed papers.

My research interests are focused on biomarker development and pathology / radiology correlation for prostate cancer and molecular diagnostics of urothelial cancer.

Christopher J.D. Wallis is a Urologic Oncologist at the University of Toronto and Mount Sinai Hospital. He obtained his Doctor of Medicine from the University of British Columbia and his Doctor of Philosophy in Clinical Epidemiology & Health Care Research from the Institute of Health Policy, Management & Evaluation at the University of Toronto and completed his clinical residency in Urology at the University of Toronto affiliated hospitals and his Society of Urologic Oncology accredited fellowship training at Vanderbilt University Medical Center. His research focuses on leveraging a variety of epidemiologic techniques to understand and improve care for patients with urologic conditions, particularly prostate cancer.

Dr Welk completed his urology residency at the University of British Columbia and then completed additional clinical training at the University of Toronto, where he specialized in the evaluation and treatment of male and female incontinence, neurogenic bladder dysfunction, and male urethral stricture disease. Dr. Welk is an Associate Professor of Surgery (Urology) and Epidemiology & Biostatics at Western University. His research has been funded by numerous national and international granting agencies and he has published over 170 peer reviewed manuscripts. He is the current vice president of the International Neurourology Society and the Neurogenic Bladder Research Group.

Dr. Alexandre Zlotta is the Director of Uro-Oncology of the Murray Koffler Urologic Wellness Centre, Mount Sinai Hospital, a Professor in the Department of Surgery (Urology), University of Toronto, and surgeon at University Health Network. Dr. Zlotta is also an Associate Member at the Lunenfeld Tanenbaum Research Institute (LTRI) at Mount Sinai Hospital, and Associate Editor for the journal ‘Bladder Cancer’ and ‘Frontiers in Oncology’ among being on several international editorial boards.

Dr. Zlotta received his MD from the Free University of Brussels and completed his PhD in Immunology at the Pasteur Institute in Brussels. Dr. Zlotta is an internationally renowned academic uro-oncologic surgeon with an extended research career that boasts success in both translational research and multi-institutional, international studies with a special interest in bladder and prostate cancer research. He has authored over 300 scientific papers. Among other awards, he has received the Matula Award and the Platinum Award of the European Association of Urology.